FINWIRES · TerminalLIVE
FINWIRES

世界各國領導人支持霍爾木茲海峽重新開放,推動實現無限制通行

-- 週五,全球領導人對霍爾木茲海峽的重新開放反應謹慎,他們歡迎這一進展,但同時在持續的安全和地緣政治擔憂下,尋求確保永久、安全的航行。 聯合國秘書長安東尼奧古特雷斯稱此舉是“朝著正確方向邁出的一步”,同時強調需要全面恢復航行權利和自由。 古特雷斯表示:“聯合國的立場仍然明確:我們需要全面恢復霍爾木茲海峽的國際航行權利和自由,並得到各方的尊重。” 週五,在巴黎舉行的會議上,歐洲領導人也表達了類似的觀點。這次會議由法國總統馬克宏和英國首相基爾·斯塔默共同主持,約有50個國家參加了會議,討論了組建一個潛在的多國特派團以保障航運安全的計劃。 馬克宏表示,應仔細評估事態發展,並指出通行仍取決於伊朗的協調以及美國持續的封鎖。斯塔默則表示,重新開放必須不只是一項短期協議。 「這必須是一個持久有效的解決方案,不能收取通行費或限制航道,」斯塔默說。 歐盟委員會主席烏爾蘇拉·馮德萊恩表示,歐盟將透過共享衛星數據和加強海上安全行動來支持相關努力,而德國則表示願意為保障航行自由做出貢獻。 「霍爾木茲海峽傳來好消息。然而,航道必須保持永久、可靠和安全。在這方面,我們與巴黎的伙伴們立場一致,」德國總理弗里德里希·默茨說。 國際海事組織表示,正在核實重新開放是否符合既定的安全和航行標準。 「航行自由原則不容談判,」國際海事組織秘書長阿塞尼奧·多明格斯說。 儘管船舶交通的恢復緩解了人們對供應中斷的擔憂,但分析師表示,停火的持久性和安全航行的清晰度將決定能源市場是趨於穩定還是面臨新的波動。 麥格理資本全球戰略主管維克托·什韋茨表示:“以色列和黎巴嫩之間的停火使得霍爾木茲海峽的開放成為可能。然而,這只能算作一項臨時且脆弱的協議。” 伊朗週五表示,在以色列和黎巴嫩達成停火協議後,已重新開放霍爾木茲海峽,允許商業航運通行。這為全球能源市場帶來了一絲喘息之機,但由於美國封鎖仍在持續,不確定性仍然存在。 德黑蘭方面表示,在停火期間,這條戰略水道對商業船舶“完全開放”,船舶可沿其港口和海事組織協調的航線航行。 據報道,近日有五艘空油輪抵達伊朗在阿拉伯灣的港口,並開始裝載原油,這標誌著霍爾木茲海峽重新開放後,海上活動開始復甦。 週五,克普勒表示,包括與阿布達比國家石油公司(ADNOC)在達斯島附近開展的液化天然氣(LNG)計畫相關的早期船舶活動,顯示海上活動正在謹慎地恢復。 然而,該分析公司表示,航線選擇、貨物裝載和安全風險仍然不明朗,市場參與者正在密切關注貨運量能否持續恢復。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703